Pase 0.5

Generic

Clonazepam.

 

Indications

It is shown for the treatment of freeze clutter, with or without agoraphobia. Freeze clutter is characterized by the event of startling freeze assaults and related concern around having extra assaults, stress approximately the suggestions or results of the attacks. It is additionally shown alone or as an aide within the treatment of the Lennox-Gastaut Disorder (petit mal variation), akinetic and myoclonic seizures. It may be shown in patients with absence seizures (petit mal) who have fizzled to reply to succinimides. The adequacy of Clonazepam in long-term utilize, that's, for more than 9 weeks, has not been efficiently examined in controlled clinical trials. The doctor who chooses to utilize Clonazepam for expanded periods ought to intermittently reevaluate the long-term value of the medication for the person's understanding.

 

Pharmacology

Pase 0.5 mg shows pharmacological properties which are common to benzodiazepines and incorporate anticonvulsive, narcotic, muscle unwinding, and anxiolytic impacts. The central activities of benzodiazepines are intervened through an improvement of the GABAergic neurotransmission at inhibitory neural connections. Within the nearness of benzodiazepines, the fondness of the GABA receptor for the neurotransmitter is upgraded through positive allosteric balance coming about in an expanded activity of discharged GABA on the postsynaptic transmembrane chloride particle flux. There is too creature information appearing an impact of clonazepam on serotonin. Creature information and electroencephalographic examinations in man have appeared that clonazepam quickly stifles numerous sorts of paroxysmal action counting the spike and wave release in nonattendances seizures (petit mal), moderate spike-wave, generalized spike-wave, spikes with transient or other areas as well as sporadic spikes and waves. Generalized EEG anomalies are more routine.

 

Dosage & Administration

Adults: The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. The maximum recommended daily dose is 20 mg.

• The initial dose for adults with panic disorder is 0.25 mg given in two divided doses. An increase to the target dose for most patients of 1 mg/day may be made after 3 days.
• Pediatric Patients: In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in two or three divided doses.

 

Interaction

Phenytoin, carbamazepine, and phenobarbital pharmacokinetics do not appear to be affected by Pase 0.5 mg. Clonazepam's impact on the metabolism of other medications has not been studied.

 

Contraindications

It ought to not be utilized in patients with a history of extreme touchiness to benzodiazepines, nor in patients with clinical or biochemical prove of noteworthy liver infection. It may be utilized in patients with open point glaucoma who are getting fitting treatment but is contraindicated in intense limit point glaucoma.

 

Side Effect

The foremost habitually happening side impacts of Pase 0.5 mg are preferable to CNS discouragement. Encounter in treatment of seizures has appeared that tiredness has happened in around 50% of patients and ataxia in around 30%. In a few cases, these may lessen with time; behavior issues have been famous in roughly 25% of patients. Anomalous eye developments, aphonia, coma, tremor, vertigo, disarray, sadness, amnesia, visualizations, mania, expanded charisma, a sleeping disorder, psychosis & palpitations may moreover happen.

 

Pregnancy & Lactation

Pregnancy: From preclinical studies, it cannot be excluded that Pase 0.5 mg possesses the possibility of producing congenital malformations. From epidemiological evaluations, there is evidence that anticonvulsant drugs act as teratogens. However, it is difficult to determine from published epidemiological reports which drug or combination of drugs is responsible for defects in the newborn. The possibility also exists that other factors e.g. genetic factors or the epileptic condition itself may be more important than drug therapy in leading to birth defects. Under these circumstances, the drug should only be administered to pregnant women if the potential benefits outweigh the risk to the fetus. During pregnancy, Pase 0.5 mg may be administered only if there is a compelling indication. Administration of high doses in the last trimester of pregnancy or during labor can cause irregularities in the heartbeat of the unborn child and hypothermia, hypotonia, mild respiratory depression, and poor.

 

Precautions & Warnings

Pase 0.5 mg may increase the incidence or hasten the beginning of generalized tonic-clonic seizures in patients who have multiple distinct forms of seizure disorders. This may necessitate the addition of or an increase in the dosage of anticonvulsants. The use of valproic acid and Pase 0.5 mg at the same time can cause absent status.

 

Therapeutic Class

Aide anti-epileptic drugs, Benzodiazepine hypnotics.

 

Storage Conditions

Store in a cool and dry place, protected from light.

 

Pharmaceutical Name

Opsonin Pharma Limited.

 

Related Products

• Epitra 0.5
• Clonatril 0.5
• Epiclon 0.5
• Clonium 0.5
• Leptic 0.5